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able, health plans in some instances may seek to develop their
own evidence. Although this can be challenging, our project pro-
vides an example of the feasibility of such an undertaking.
PCASE11
SYNAGIS 2005–2006 SEASON
Gill P, Parmar K, Jan SA
Horizon Blue Cross Blue Shield of New Jersey, Newark, NJ, USA
Organization: Horizon Blue Cross Blue Shield of New Jersey.
Problem or Issue Addressed: Synagis for RSV.
Goals: To assess retrospective rate of RSV hospitalization and/or
ER visit in members who were approved for Synagis for the
season and in members who were denied Synagis for the season.
Outcomes items used in the decision: Horizon criteria for Synagis
is based on the AAP guidelines for RSV.
Implementation Strategy: After the peak RSV 2005–2006 season
was over, Horizon did a retrospective analysis on all members
who requested for Synagis. We reviewed the medical data for
claims of RSV hospitalization, RSV ER visits, or RSV ofﬁce
visits. We pulled the following diagnosis: Respiratory syncytial
virus −079.6; Respiratory syncytial virus, bronchiolitis −466.11;
and Respiratory syncytial virus, pneumonia −480.1
Results: We had a total of 1028 members request for Synagis.
Out of which 338 members (32.9%) did not meet the criteria
and 690 members (67.1%) did meet the criteria. Out of the 338
members, 6 members (1.8%) had documented claim of RSV
infection. They include the following:
• 1 patient was suspected for an admission
• 1 patient was denied and 7 days after had a hospitalization
• 1 patient was denied and 12 days after had a hospitalization
• 2 patients were denied AFTER the hospitalization
• 1 patient seemed to have a RSV hospitalization
Leasons Learned: Horizon’s Synagis criteria is based on the AAP
criteria. We will continue to monitor for RSV related hospital-
ization, RSV related ER visits, and RSV related ofﬁce visits every
season.
PCASE12
DETERMINING THE VALUE OF DIAGNOSTIC/GENETIC
TESTING TO INFORM HEALTH PLAN DECISION MAKING:
ONCOTYPE DX AS A CASE STUDY
Watkins J1, Bresnahan BW2,Veenstra DL2, Garrison LP2, Sullivan SD2
1Premera Blue Cross, Mountlake Terrace, WA, USA, 2University of
Washington, Seattle, WA, USA
Organization: Premera Blue Cross Pharmacy and Therapeutics
Committee (P&T). Premera is a 1.6 million member regional
commercial health plan in the Paciﬁc Northwest.
Problem or Issue Addressed: Need to determine medical neces-
sity criteria and appropriate cost-effective use of Oncotype DX,
a genomic test that predicts the risk of distant recurrence fol-
lowing successful surgical resection of early stage, node negative,
estrogen receptor positive b.
Goals: To pilot the use of disease-based cost-effectiveness models
in helping medical policy decision makers to determine the
appropriate place in therapy for a genomic diagnostic test that
is the ﬁrst of many similar products to reach market.
Outcomes items used in the decision: The assessment for the
decision will include evaluating the available body of clinical and
economic evidence. Information related to cost-effectiveness will
be evaluated from the published literature and from evidence
provided from the sponsor company to the health plan, follow-
ing an unsolicited request for this information. The health plan
requested that the evidence package follow the suggested
approach outlined in a 2006 University of Washington, Phar-
maceutical Outcomes Research and Policy Program and Public
Health Genetics Program joint-guidance document, “Evidence
and Transparency Recommendations to Support Coverage and
Reimbursement Decisions for Medical Testing.” The speciﬁc out-
comes to be evaluated for the diagnostic are the clinical effects
and the reliability of the test, economic endpoints related to the
cost of improving overall survival and quality-adjusted survival,
and the sensitivity analyses presented in published economic
models supporting the product. The guidance document suggests
a presentation of clinical information, as well as information on
the costs and consequences and/or cost-effectiveness of new
medical testing technologies.
Implementation Strategy: The case study evaluation process con-
sists of four primary stages. First, a preliminary review of evi-
dence was performed using published literature and the initial
product-related information provided by the sponsor company.
Second, a full evidence support dossier was requested from the
sponsor and will be evaluated by the research team. Third, addi-
tional assessments and sensitivity analyses will be performed to
identify meaningful metrics for product evaluation moving
forward. Fourth, the results are to be presented to the Pharmacy
and Therapeutics Committee for scientiﬁc review, and then to
the Medical Policy Committee, where the ﬁnal decision is made.
The resulting policy will then be implemented through Premera’s
routine medical necessity review process.
Results: The preliminary clinical and economic evaluations
suggest that additional evidence would be helpful to more fully
inform health plans regarding coverage and reimbursement deci-
sions. The sponsor company response to the product information
request (i.e., dossier) is expected to assist the health plan with
evaluating the most recent and complete available Oncotype Dx-
related evidence. The evidence presentation format suggested in
the medical testing guidance allows a product developer the
opportunity to describe and present information related to the
clinical and economic value of their products. An evaluation of
the economic model parameters for which the cost-effectiveness
estimates are most sensitive (e.g., lower-risk recurrence score
patients receiving adjuvant chemotherapy treatment) can provide
ranges of cost-effectiveness related to the expected value of the
diagnostic test, depending on whether the test results inﬂuence
changes in clinical behavior (i.e., forgoing chemotherapy).
Lessons Learned: Clinical-effectiveness and cost-effectiveness
evaluations for medical diagnostic products are increasing in
rigor and in the expectations of health plans for evidence of clin-
ical utility. The value of utilizing higher-priced medical products
for serious illness can be strengthened when diagnostics can
assist with the identiﬁcation of appropriate patient sub-popula-
tions and the likelihood and expected magnitude of clinical and
economic response. However, new diagnostics tend to have less
evidence for evaluation compared to new pharmaceuticals. Pro-
vided that most medical products have limited real world effec-
tiveness data at launch, which may take years to accumulate,
effectiveness modeling can be useful to aid decision-making.
Evaluating the evidence for Oncotype Dx in relation to its clin-
ical and economic net beneﬁt to patients serves as a useful case
for piloting the evidence guidance document and for considering
the health and economic effects of diagnostic testing for difﬁcult
to treat and recurring diseases, such as breast cancer. Standard-
izing the process for and improving the transparency of evidence
evaluation for medical tests should contribute to more efﬁcient
and consistent resource allocation.
